Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAHC-II: Response-Guided Treatment for Recent HCV
NCT01336010Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Aug 2011
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a, ribavirin in hepatitis C virus infection, sponsored by The Kirby Institute. Started Aug 2011; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01336010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336010.